Pekin Hardy Strauss’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Pekin Hardy Strauss’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-19,476	Closed	-$983K	–	194
2014 Q4	$983K	Buy	+19,476	New	+$949K	0.14%	114

Other funds holding IHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AWA

ARS Wealth Advisors St. Petersburg, Florida $556M AUM 30.03% 1-Year Est. Return

BCM

Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BWM

Braver Wealth Management Needham, Massachusetts $616M AUM 12.48% 1-Year Est. Return

Pekin Hardy Strauss's IHE Position: Q1 2015 in Review

Pekin Hardy Strauss sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2015, closing a stake of 19,476 shares — an estimated $983K sold.

Pekin Hardy Strauss first reported a position in IHE in Q4 2014 and held it in 1 quarter. The position peaked at $983K in Q4 2014. 111 funds tracked by Wall St. Rank hold IHE as of Q1 2015.

Pekin Hardy Strauss reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2015 after selling out during the quarter.
Pekin Hardy Strauss sold 19,476 iShares US Pharmaceuticals ETF shares in Q1 2015, an estimated $983K.
Pekin Hardy Strauss first reported a position in iShares US Pharmaceuticals ETF in Q4 2014 and held it in 1 quarter.
Pekin Hardy Strauss's iShares US Pharmaceuticals ETF position peaked at $983K in Q4 2014.
111 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2015.

Based on Pekin Hardy Strauss's 13F filing for Q1 2015, filed 11 May 2015.